Stage 1 prostate adenocarcinoma is localized, non-aggressive, and often detected through routine screenings like PSA tests and DREs. Diagnosis involves PSA levels, Gleason scores, and possibly ...

Serum biomarkers in metastatic castration-resistant prostate cancer (mCRPC) patients receiving [177Lu]Lu-PSMA-617 therapy: Post hoc analysis of a phase II clinical trial. Individual patient data (IPD) ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Genitourinary medical oncologist Dr. Michael Morris is part of a new MSK program focused on better treatments for neuroendocrine cancers, which sometimes develop when prostate and lung cancers become ...

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...